The Latest Breaking News from 23andMe

Does our DNA really determine our intelligence and health?

In a recent article from Nature Genetics_, scientists raise concerns over the social impacts of recent advances in genomics - i.e. the study of genomes, or in other words, the genetic material of an individual or species. In passages bringing to mind the dystopian sci-fi film Gattaca, they describe a…

The Conversation · Apr 23, 2023

Who Owns Your Brain Data?

Nita A. Farahany's The Battle for Your Brain shows how neurotech can help, or hurt, human liberty.

Reason · Mar 18, 2023

Asia’s richest man Mukesh Ambani to foray into genome testing with Rs 12,000 kit

MUMBAI: Billionaire Mukesh Ambani’s group is getting into genetic mapping, looking to make a health care trend led by disruptive US startups like 23andMe more affordable and widespread in India’s growing consumer market.

The Times of India · Mar 2, 2023

At-home DNA tests aren’t that reliable – and the risks may outweigh the benefits

The field of genomic science is rapidly advancing, with commercial DNA tests becoming affordable and popular.

The New Daily · Nov 29, 2022

At-home DNA tests just aren’t that reliable – and the risks may outweigh the benefits

The field of genomic science is rapidly advancing, with commercial genetic tests becoming affordable and popular.

The Conversation · Nov 29, 2022

Texas woman found by family 51 years after being kidnapped as baby

Melissa Highsmith, who family say was abducted in Fort Worth in 1971, located in South Carolina, more than 1,000 miles away

The Guardian - US · Nov 28, 2022

A miracle: Long-lost brother and sister find each other at Fort Worth hospital

FORT WORTH, Texas — Raymond Turner was at work when he got a notification from 23andMe that his DNA test results were ready.

Tribune News Service · Aug 17, 2022

How to be a CEO: 23andme’s Anne Wojcicki on revolutionising the biotech industry

Plus, the importance of instant feedback

Evening Standard · Jul 18, 2022

Should You Scoop Up Shares of 23andMe?

23andMe (ME) saw its shares slump in price after it reported its fourth-quarter earnings results last month. However, given the company's multiple FDA authorizations for over-the-counter genetic health risk reports, would it be worth scooping up its shares now? Read on, let's find out.

StockNews.com · Jun 6, 2022

Women twice as likely to suffer from long Covid as men, study suggests

Top long Covid symptoms reported by survey participants included brain fog, fatigue, and shortness of breath

The Independent UK · May 25, 2022